Montelukast Sodium Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 1.07 Bn

Forecast Year, 2035

USD 1.88 Bn

CAGR, 2026 - 2035

5.80%

Report Coverage

Global

What is the Montelukast Sodium Market Size in 2026?

The global montelukast sodium market size accounted for USD 1.07 billion in 2025 and is predicted to increase from USD 1.13 billion in 2026 to approximately USD 1.88 billion by 2035, expanding at a CAGR of 5.80% from 2026 to 2035. The montelukast sodium market is driven by growing demand for effective treatments for respiratory disorders and allergies.

Key Takeaways

• North America dominated the global montelukast sodium market with a share of 35.00% in 2025.
• The Asia Pacific is expected to grow at the fastest CAGR of 6.8% during the forecast period.
• By dosage form, the tablets segment held a dominant position in the market, accounting for 70.00% share in 2025.
• By dosage form, the oral granules segment is the second-largest shareholder and is expected to grow at the fastest CAGR of 6.5% between 2026 and 2035.
• By application, the asthma segment accounted for a major revenue share of 50.00% in the market in 2025.
• By application, the allergic rhinitis segment is the second-largest shareholder and is expected to grow at the fastest CAGR of 6.5% between 2026 and 2035.
• By distribution channel, the hospital pharmacies segment led the global market with a share of 40.00% in 2025.
• By distribution channel, the retail pharmacies segment is the second-largest shareholder and is expected to grow at a significant rate between 2026 and 2035.

Market Overview

Montelukast sodium is a leukotriene receptor antagonist, which is commonly used in the treatment of respiratory and other allergic conditions, such as asthma, exercise-induced bronchospasm, allergic rhinitis, urticaria, and primary dysmenorrhea. Its mechanism of action is to inhibit leukotrienes, inflammatory chemicals in the body that lead to airway constriction, mucus production, and swelling. The growing geriatric population, which has a higher risk of developing chronic respiratory diseases, is driving market growth. Furthermore, the expansion of healthcare infrastructure, increased awareness, and addition of montelukast in clinical management recommendations are contributing to market growth.

Montelukast Sodium Market Trends

• The rising geriatric population worldwide is contributing to a higher prevalence of chronic respiratory diseases. This significantly increases the use of montelukast sodium, particularly in combination therapies, for effective management of asthma and allergy-related conditions.
• Growing emphasis on research & development is leading to the creation of improved drug formulations and combination therapies. These advancements are enhancing treatment efficacy and expanding the clinical applications of montelukast sodium in respiratory care.
• Expanding healthcare infrastructure and improved access to medical services in emerging economies are supporting market growth. More patients now have access to proper diagnosis and long-term treatment for asthma, allergies, and other respiratory conditions.
• The inclusion of montelukast sodium in standard treatment protocols, along with increased awareness among healthcare professionals about its preventive benefits, is boosting its adoption as a maintenance therapy for asthma and other allergic respiratory disorders.

Market Scope

Market Dynamics

Drivers

Increasing Prevalence of Respiratory Diseases

One of the major factors driving the montelukast sodium market is the increasing prevalence of respiratory diseases, such as asthma, allergic rhinitis, and exercise-induced bronchospasm. This rise is driven by increasing air pollution, urbanization, smoking habits, climate change, and the predisposition of genes. Additionally, lifestyle changes and prolonged environmental exposure have further contributed to the growing burden of respiratory disorders. In response, governments and healthcare organizations have placed greater emphasis on early diagnosis and long-term management of asthma and allergies. This, in turn, is boosting the need for montelukast sodium as part of standard treatment regimens.

Growing Awareness and Adoption of Asthma Management Therapies

Through patient education, public health campaigns, and efforts by healthcare providers, awareness of asthma, allergic rhinitis, and other respiratory diseases is rising worldwide. As a result, the adoption of pharmacological treatments is growing, including the use of montelukast sodium as a preventive therapy. Montelukast is widely used in maintenance treatment due to its ability to reduce the frequency of asthma attacks and relieve allergy symptoms. Its preventive benefits and ease of use make it a preferred option for long-term management of asthma and related allergic conditions.

Restraint

Generic Competition

The expiration of the patent for montelukast sodium presents a greater challenge to the market because it leads to intense competition from generic manufacturers. Also, many countries increasingly rely on low-cost generic imports to meet domestic healthcare needs, which limits the growth potential of branded products. This price-sensitive environment compels companies to adopt competitive pricing strategies while maintaining product quality. Furthermore, the widespread availability of generic alternatives has increased patient choice, thereby reducing brand loyalty and intensifying market competition.

Opportunity

Advancements in Drug Delivery Systems

Innovations in drug delivery systems create immense opportunities in the montelukast sodium market by enhancing patient convenience and treatment adherence. Manufacturers are increasingly developing combination formulations with other active ingredients to reduce pill burden and improve therapeutic outcomes, particularly for patients requiring multiple medications. Additionally, advanced delivery technologies, such as rapidly dissolving tablets and flavored or colored granules, are improving compliance, especially among pediatric patients. For adults, extended-release formulations offer sustained drug action and greater convenience, further supporting adherence to long-term treatment regimens.

Segment Insights

Dosage Form Insights

Montelukast Sodium Market Share, By Dosage Form, 2025-2035 (%)

Tablets Held a 70.00% Share of the Montelukast Sodium Market in 2025

The tablets segment held a dominant position in the market with a share of 70.00% in 2025. This is because of their convenience, patient compliance, and widespread use in clinical settings. Tablets are the most popular form of controlling asthma, allergic rhinitis, and other respiratory problems at all ages. Innovation of film-coated tablets provides greater stability, masks unpleasant taste, and protects the drug from environmental exposure. Chewable tablets have gained immense traction among children and elderly patients. Tablets are portable, easy to store, and able to deliver standardized dosing, all of which contribute to better adherence to long-term therapy.

The oral granules segment held a 25.00% share of the market in 2025 and is expected to grow at a CAGR of 6.5% during the projection period, driven by an increasing demand for granules among children and patients who have difficulties in swallowing. Granules offer precise dosing, allowing for adjustments based on factors such as age, weight, or specific treatment needs, making them ideal for pediatric and elderly populations. Additionally, granules are often flavored to improve taste and ease of consumption, which enhances patient adherence and long-term compliance with therapy.

Application Insights

Montelukast Sodium Market Share, By Application, 2025-2035 (%)

The Asthma Segment Held a 50.00% Share of the Montelukast Sodium Market in 2025

In 2025, the asthma segment dominated the global market while holding a major share of 50.00%, owing to the high global prevalence of asthma and its widespread treatment with montelukast sodium as a first-line therapy. Montelukast is effective in preventing asthma attacks, reducing inflammation, and improving lung function, making it a preferred option for long-term asthma management. Additionally, the rising awareness of asthma treatment, coupled with the growing focus on patient adherence through convenient drug delivery methods like chewable tablets and rapidly dissolving formulations, further drives the dominance of this segment.

The allergic rhinitis segment held a 35.00% market share in 2025 and is expected to grow at a CAGR of 6.5% during the projection period. The growth of this segment is primarily driven by the increasing prevalence of seasonal allergies and respiratory issues. Factors such as heightened exposure to allergens, urban air pollution, and changes in pollen distribution due to climate shifts have contributed to a rising number of allergic rhinitis cases. Montelukast sodium is favored for its ability to prevent and treat symptoms like sneezing, nasal congestion, and itchy eyes, while its oral administration and ease of use make it especially popular among children with recurrent or chronic allergic symptoms, further enhancing treatment adherence.

The chronic urticaria segment held a 10.00% share of the market in 2025 and is expected to grow at a notable CAGR of 5% during the projection period. This is mainly due to the increasing recognition of montelukast's effectiveness in managing this condition, which is characterized by recurrent hives and itching. With chronic urticaria often being triggered by allergic reactions, montelukast helps to reduce inflammation and alleviate symptoms, making it a valuable treatment option for patients.

Distribution Channel Insights

Retail Pharmacies Led the Market With a 45.00% Share in 2025

The retail pharmacies segment registered dominance in the montelukast sodium market with a share of 45.00% in 2025. This is primarily due to their widespread accessibility and convenience for patients seeking over-the-counter or prescription medications. Retail pharmacies serve as the primary point of contact for patients, offering easy access to montelukast sodium in various formulations, such as tablets and granules, which enhances patient adherence.

Montelukast Sodium Market Share, By Distribution Channel, 2025-2035 (%)

The hospital pharmacies segment held a 40.00% share of the market in 2025 and is expected to grow at a CAGR of 5.2% during the projection period as a result of the increasing number of patients being treated for chronic respiratory conditions, such as asthma and allergic rhinitis, in hospital settings. Hospitals are often where patients with severe or complex cases first receive diagnosis and treatment, leading to a higher volume of montelukast sodium prescriptions. Additionally, the availability of montelukast as part of comprehensive treatment plans in hospitals, combined with the rising adoption of advanced therapies for respiratory disorders, is driving the growth of this segment.

The online pharmacies segment held a 15.00% market share in 2025 and is expected to grow at the fastest CAGR of 8% during the projection period. This is mainly due to the rapid shift toward e-commerce and the convenience they offer patients in purchasing medications from home. Additionally, online pharmacies often provide competitive pricing, home delivery, and easier access to various drug formulations, which further contributes to their growing popularity among patients seeking long-term management of asthma and allergic conditions.

Regional Insights

North America Montelukast Sodium Market Size and Growth 2026 to 2035

The North America montelukast sodium market size is estimated at USD 374.50 million in 2025 and is projected to reach approximately USD 667.40 million by 2035, with a 5.95% CAGR from 2026 to 2035.

Why Did North America Led the Global Montelukast Sodium Market in 2025?

North America dominated the global montelukast sodium market with a major share of 35.00% in 2025 due to the rising prevalence of asthma, rhinitis, and other chronic respiratory infections. Increasing air pollution, urbanization, lifestyle changes, and genetic predisposition to respiratory diseases have created a higher demand for effective prevention and maintenance therapies. Enhanced patient awareness, proactive disease management programs, and routine asthma and allergy screenings have also contributed to the broader adoption of montelukast sodium. Furthermore, its proven efficacy, strong safety profile, and ability to reduce respiratory-related hospitalizations make montelukast a preferred choice among healthcare providers in North America.

U.S. Montelukast Sodium Market Size and Growth 2026 to 2035

The U.S. montelukast sodium market size is calculated at USD 280.88 million in 2025 and is expected to reach nearly USD 503.89 million in 2035, accelerating at a strong CAGR of 6.02% between 2026 and 2035.

U.S. Montelukast Sodium Market Analysis

The U.S. is the major contributor to the market within North America, supported by its well-established healthcare infrastructure that includes hospitals, outpatient clinics, and diagnostic facilities. The presence of a robust pharmaceutical sector, along with the concentration of leading pharmaceutical companies , ensures that both branded and generic montelukast sodium products are produced, distributed, and made widely available in large quantities.

What Makes Asia Pacific the Fastest-Growing Region in the Montelukast Sodium Market?

Asia Pacific held a 25.00% market share in 2025 and is expected to grow at the fastest CAGR of 6.8% during the projection period, driven by the increasing prevalence of respiratory illnesses such as asthma and allergic rhinitis, as well as the rapid expansion of healthcare systems. The rapid urbanization, industrialization, and lifestyle changes, combined with the rising burden of respiratory diseases, has created a growing demand for prevention and treatment options like montelukast sodium. Additionally, the rising awareness among healthcare providers and patients about the benefits of long-term asthma and allergy management is further fueling the adoption of montelukast sodium in the region.

Japan Montelukast Sodium Market Analysis

The market in Japan is growing due to its highly developed healthcare system and universal health coverage, which ensures affordable access to medications like montelukast sodium for the entire population. Pharmaceutical products in Japan are rigorously regulated and certified by the Pharmaceuticals and Medical Devices Agency (PMDA), guaranteeing their safety, efficacy, and quality. The country's strong focus on enhancing public health contributes to the widespread adoption and usage of montelukast sodium, making it a preferred treatment option for respiratory conditions.

Why is Europe Experiencing Notable Growth in the Montelukast Sodium Market?

Europe held a 25.00% share of the market in 2025 and is expected to grow at a notable CAGR of 5.3% during the projection period, driven by the rising prevalence of respiratory diseases such as asthma, allergic rhinitis, and seasonal allergies. Environmental factors like increased air pollution, climate change, and urbanization have contributed to the growing incidence of these conditions across the region. Furthermore, increasing awareness among both patients and healthcare providers about the benefits of proactive respiratory disease management is driving the adoption of montelukast sodium in Europe.

UK Montelukast Sodium Market Analysis

The UK plays a key role in the European market, with the Medicines and Healthcare products Regulatory Agency (MHRA) ensuring that pharmaceutical products meet high standards for safety, efficacy, and quality. The regulatory framework in the UK, along with broader European policies, promotes the use of generic drugs, improving accessibility and affordability for patients. Additionally, the area benefits from a well-developed healthcare infrastructure, robust patient education programs, and proactive government initiatives, all of which contribute to the rapid growth of the market.

Montelukast Sodium Market Value Chain Analysis

Montelukast Sodium Market Companies

• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (Viatris)
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Ltd.
• Zydus Lifesciences Ltd.
• Lupin Limited
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Sandoz (Novartis Division)
• Torrent Pharmaceuticals Ltd.
• Alkem Laboratories Ltd.
• Apotex Inc.

Segments Covered in the Report

By Dosage Form

• Tablets
• Film-coated Tablets
• Chewable Tablets
• Oral Granules
• Others

By Application

• Asthma
• Allergic Rhinitis
• Chronic Urticaria
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa